CSL Behring Marks World Hemophilia Day by Renewing Pledge to World Federation of Hemophilia
CSL Behring to Donate 10 Million IUs of its Bleeding Disorder Protein Therapies and to Contribute More than $1.1 Million in Financial Support to WFH
MONTREAL and KING OF PRUSSIA, Pa. — 14 April 2015
In recognition of World Hemophilia Day April 17, the
World Federation of Hemophilia (WFH) and
CSL Behring announced today that CSL Behring has once again committed to donating bleeding disorder protein therapy international units (IUs) to the WFH Global Alliance for Progress (GAP) Program and other WFH programs, as well as making significant financial contributions to WFH.
As part of the new agreement, CSL Behring will provide 10 million IUs of one or more of its products from its broad portfolio of bleeding disorder protein therapies to the WFH over the period of three years, beginning in 2016. The GAP Program strives to improve the diagnosis and treatment of bleeding disorders in developing countries. In 2009, CSL was the first biotherapies company in the world to make a multiyear commitment to WFH to aid the GAP Program with humanitarian aid coagulation factor donations over an extended period of time. CSL Behring will also provide more than $1.1 million in financial support to WFH’s Corporate Partner and GAP programs over the three year period. World Hemophilia Day is promoted by WFH to increase global awareness of hemophilia and other inherited bleeding disorders.
"WFH established the GAP Program to advance our vision of Treatment for All, working to improve diagnosis and access to care for the millions of people who have a rare bleeding disorder yet remain without treatment,” said WFH President Alain Weill. "CSL Behring shares WFH’s vision in improving diagnosis and treatment access. We are once again grateful for the generous pledge made by CSL Behring as we strive to help fulfill our commitment to introduce clotting factor concentrates in developing countries where people who are living with a bleeding disorder may not be able to access appropriate treatment.”
Since its first donation in 2009, CSL Behring has provided nearly 14 million IUs of its bleeding disorder protein therapies to treat people with hemophilia or von Willebrand disease (VWD) in developing countries.
"CSL Behring has long been at the forefront of enabling people with serious conditions to lead normal and healthy lives,” said Paul Perreault, CEO and Managing Director of CSL Limited. "The GAP Program aligns with CSL Behring’s goal to make meaningful differences in the lives of people who are living with serious diseases, such as hemophilia or von Willebrand disease. We look forward to our continued partnership with WFH as we work together to improve treatment access in developing countries around the world.”
About the Global Alliance for Progress Program
The Global Alliance for Progress (GAP) Program is a healthcare development project launched in 2003, now in its Second Decade phase (2013-2022). The overarching goals for the GAP Program will be to increase by 50,000 the worldwide number of people identified/diagnosed with a bleeding disorder, as well as to ensure that 50 percent of those newly diagnosed are from the world’s most impoverished countries. CSL Behring supports the WFH GAP Program as one of the program sponsors.
About the World Federation of Hemophilia
For over 50 years, the World Federation of Hemophilia (WFH), an international not-for- profit organization, has worked to improve the lives of people with hemophilia and other inherited bleeding disorders. Established in 1963, it is a global network of patient organizations in 127 countries and has official recognition from the World Health Organization. Visit WFH online at
About CSL Behring
CSL Behring is a leader in the plasma protein therapeutics industry. Committed to saving lives and improving the quality of life for people with rare and serious diseases, the company manufactures and markets a range of plasma-derived and recombinant therapies worldwide.
CSL Behring therapies are used around the world to treat coagulation disorders including hemophilia and von Willebrand disease, primary immune deficiencies, hereditary angioedema and inherited respiratory disease, and neurological disorders in certain markets. The company’s products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent hemolytic disease of the newborn.
CSL Behring operates one of the world’s largest plasma collection networks, CSL Plasma. CSL Behring is a global biopharmaceutical company and a member of the CSL Group of companies. The parent company,
CSL Limited (ASX:CSL), is headquartered in Melbourne, Australia. For more information, visit
World Federation of Hemophilia